

CANADIAN
DUPUYTREN
SOCIETY



CANADIAN DUPUYTREN SOCIETY- ANNUAL REPORT 2022






TABLE OF CONTENTS

The Year in Review

- Joint Innovation Grant with the Arthritis Society
- Patient's enquiries for information
- Privacy Officer
- Measure Yourself Medical Outcome Profile

MESSAGE TO THE COMMUNITY

THE YEAR IN REVIEW

CANADIAN
DUPUYTREN
SOCIETY



The 2022 year was a year of IT migration for the Canadian Dupuytren Society, as many resources were devoted to the design of the new website, as well as the inclusion of new online information. Patients are always interested in new, up-to-date information on the disease and treatments, especially on non-invasive and early treatments, including some new treatments that have been offered in Canada by health professionals. Special attention was given to approaches to medical societies for grant partnerships. A potential questionnaire was reviewed and translated to gather information on key issues and challenges for patients.

Joint Innovation Grant with the Arthritis Society

The Arthritis Society of Canada and The Dupuytren's Society of Canada have joined forces to offer a new complementary funding opportunity of up to \$10,000 in research through the 2023 Ignite Innovation Grant program. Dupuytren's disease and arthritis share many common characteristics, such as their debilitating potential, the lack of a cure, and a significant impact on the anxiety and mental health of those affected. Studies that may be funded will include people with arthritis who also have the symptoms of Dupuytren's disease.



THE YEAR IN REVIEW – CONT'D

CANADIAN
DUPUYTREN
SOCIETY



Patient's enquiries for information

The Society has experienced a steady increase in requests for information about Dupuytren's disease and related conditions, as well as the treatments available in Canada and the practitioners who provide them. Although migration has made it difficult to compile statistics, we have seen a growing interest in participating in clinical studies and testing new treatments.

Patients who write in also share their knowledge and resources, thereby increasing the information base and forcing some critical questioning of invasive treatments proposed today to patients in a later stage of the disease.

The most common requests were for names of specialists for treatment. Requests for information on treatments available in Canada have also emerged, including hyaluronidase injections and massage.

Privacy Officer

Since the company plans to send out newsletters, we have determined that it is necessary to appoint a privacy commissioner for the information collected in order to comply with Canadian and various provincial regulations.





Measure Yourself Medical Outcome Profile

In agreement with the developers, we carried out a translation process of the Measure Yourself Medical Outcome Profile (MYMOP), a generic tool that aims to assess general health status through an individualized measure of symptoms and the activities that affect them. The aim is to obtain a picture of symptoms and their main constraints as reported by patients without external influence. Other questionnaires may also be evaluated by the Society.



Testimonies :

The CDS receives regular testimonies from patients, sharing their good, and bad experience with the health system and the advice they get.



FINANCIAL INFORMATION

CANADIAN
DUPUYTREN
SOCIETY



The Canadian Dupuytren Society (“CDS”) financial position at year end remains strong with cash reserves exceeding \$32,000. For the year ended December 31, 2022, total revenues generated amounted to more than \$17,000 and expenditures amounted to approximately \$23,800. The majority of expenditures, totaling \$18,571 related to the continued development of the CDS website. It is expected that the final website development costs will be incurred in 2023 as the website is substantially complete. Operational costs for general and administrative costs incurred in the year remain low and totaled approximately \$5,300.

For 2023 we are budgeting to raise \$31,000 of revenue and are projected to incur approximately \$31,000 in expenditures. The majority of our budgeted expenditures, approximately \$30,600, will be incurred and relate to our charitable program costs.

	2022	2021
Cash	32,732	37,228

	2022	2021
Gifts received	17,127	31,513
Management expenses	3,129	350
Charitable expenditures	20,137	6,904
Fundraising expenditures	571	1,049



Our mission

- To promote health by leading the fight against Dupuytren's disease (DD) in Canada by helping people with DD live a healthy and functional life while we work to find a cure.
- To promote health by finding the best available care and treatment for people suffering from DD and the related Ledderhose disease (LD).
- To advance education related to DD by providing latest services and educational material to the public.
- To promote health by encouraging the search for the underlying causes and subsequent cures for DD and LD.

ORGANIZATIONAL GOALS

- *Expanding the CDS website*
- *Funding of research on the prevalence of DD*
- *Clinical information exchange*

Board of Directors :

Cindy L. Andrew, Chair of the Board
Paule Gauthier, President
Bruce L Pachkowski, Treasurer
Nathalie Fisette-Caza, Secretary
David O'Gorman, Medical Advisory Board coordinator
Anne Vezina
Mary Christidis

CANADIAN
DUPUYTREN
SOCIETY

